92739-63-4
Chemical Structure
TMPyP tetrachloride
- CAS No.: 92739-63-4
- Formula:C44H38Cl4N8
- Molecular Weight:820.64
SMILES: C[N+](C=C1)=CC=C1/C(C2=CC=C(/C(C3=CC=[N+](C)C=C3)=C4N=C(/C(C5=CC=[N+](C)C=C5)=C6C=C/C(N/6)=C7\C8=CC=[N+](C)C=C8)C=C\4)N2)=C9C=CC7=N\9.[4Cl-]
Biological Activity: TMPyP tetrachloride is a quadruplex-specific ligand. TMPyP tetrachloride inhibits the interaction between G-quadruplexes and IGF-1. TMPyP tetrachloride is a telomerase inhibitor and inhibits cancer cells proliferation. TMPyP tetrachloride is also a stabilizer of nucleic acid secondary structure and an acetylcholinesterase inhibitor. Besides, TMPyP tetrachloride has antiviral activity against SARS-CoV-2[1][2][3][6].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
TMPyP tetrachloride | 98.30% | TMPyP tetrachloride is a quadruplex-specific ligand. TMPyP tetrachloride inhibits the interaction between G-quadruplexes and IGF-1. TMPyP tetrachloride is a telomerase inhibitor and inhibits cancer cells proliferation. TMPyP tetrachloride is also a stabilizer of nucleic acid secondary structure and an acetylcholinesterase inhibitor. Besides, TMPyP tetrachloride has antiviral activity against SARS-CoV-2. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Chen H, et al. Insuline-like growth factor type I selectively binds to G-quadruplex structures. Biochim Biophys Acta Gen Subj. 2019 Jan;1863(1):31-38. [Content Brief]
- [2]. Fujimori J, et al. Antitumor effects of telomerase inhibitor TMPyP4 in osteosarcoma cell lines. J Orthop Res. 2011 Nov;29(11):1707-11. [Content Brief]
- [3]. Fujiwara N, et al. a Stabilizer of Nucleic Acid Secondary Structure, Is a Novel Acetylcholinesterase Inhibitor. PLoS One. 2015 Sep 24;10(9):e0139167. [Content Brief]
- [6]. Qin G, et al. RNA G-quadruplex formed in SARS-CoV-2 used for COVID-19 treatment in animal models. Cell Discov. 2022 Sep 6;8(1):86. [Content Brief]
